By Phebe Hong It happens every year like clockwork: Apple releases a new iPhone, and then hordes of people rush to buy it, despite still owning perfectly functional older models. We’re willing to shell out hundreds of dollars for a few extra camera features and new colors. As a result, Apple profits. A similar phenomenon…
By Ameet Sarpatwari, Charlie Lee, Frazer Tessema, and Aaron S. Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division.
By Rahul Nayak Recently, there has been a lot of media attention on galling price hikes of generic drugs. Historically, the social contract in pharmaceutical pricing has been tolerating expensive brand-name drugs while they have been on patent (a government-granted monopoly), followed by allowing low cost generics to rush to market after patent expiration. Yet…
By Jonathan J. Darrow Brand-name pharmaceutical manufacturers have long been known to try to protect and extend their market exclusivity periods by obtaining patents on a drug’s substance (“primary patents”) and also on its peripheral features, such as formulations or methods of manufacture (“secondary patents”). A new study describes an emerging phenomenon of “tertiary patents,”…
Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…
Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…
By James Love On November 17, 2017, Genentech, a subsidiary of the giant Swiss drug company Roche, together with City of Hope, a charity, filed a complaint in a U.S. District Court, seeking an injunction to block introduction of a Pfizer biosimilar version of Herceptin (INN: trastuzumab), as well as other remedies to infringement, including…
Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…
Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…
By Ameet Sarpatwari, Michael S. Sinha, and Aaron S. Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division. Below are the abstracts/summaries for papers identified…
